RHYTHM PHARMACEUTICALS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Rhythm Pharmaceuticals (RYTM) launched IMCIVREE in Japan for acquired hypothalamic obesity, the first approved treatment for this condition in the country. The drug was included in Japan's National Health Insurance list, following MHLW approval in August. Rhythm estimates 5,000-8,000 people in Japan may have this condition.
H.C. Wainwright raised its price target for Rhythm Pharmaceuticals (RYTM) to $130 from $105, maintaining a Buy rating. The stock trades at $90.78, with analysts' targets ranging from $105 to $160. Japan approved IMCIVREE for acquired hypothalamic obesity, supported by Phase 3 trial data. Rhythm reported Q2 2026 earnings, with revenue of $71.26 million, beating estimates. The company is not yet profitable but has 89% gross margins and 54% revenue growth over the last year.
Rhythm Pharmaceuticals (RYTM) announced Health Canada approved IMCIVREE for weight management in patients with acquired hypothalamic obesity, expanding its existing approvals. The drug is now indicated for patients aged four and older. The company expressed gratitude to the Canadian patient and healthcare community.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning RYTM (RHYTHM PHARMACEUTICALS, INC.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent RYTM coverage spans regulation, financial news and technology.
In the last 30 days, RYTM insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($5.1M). The most active reporter was Meeker David P, President and CEO, with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The Japan launch opens a new market for Rhythm, potentially boosting sales and expanding its addressable patient base.
Approval unlocks a new market and supports a higher valuation.
Regulatory approval expands market opportunity and may boost sales and share price.
Potential revenue uplift and market re‑rating for Rhythm Pharmaceuticals.
Regulatory approval unlocks a new patient population in Canada, likely boosting sales and stock momentum.
AlphAI scores every news story that mentions RYTM with an AI model for sentiment and relevance, and aggregates insider trades from RHYTHM PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rhythm Pharmaceuticals (RYTM) launched IMCIVREE in Japan for acquired hypothalamic obesity, the first approved treatment for this condition in the country. The drug was included in Japan's National Health Insurance list, following MHLW approval in August. Rhythm estimates 5,000-8,000 people in Japan may have this condition.
2 min readH.C. Wainwright raised its price target for Rhythm Pharmaceuticals (RYTM) to $130 from $105, maintaining a Buy rating. The stock trades at $90.78, with analysts' targets ranging from $105 to $160. Japan approved IMCIVREE for acquired hypothalamic obesity, supported by Phase 3 trial data. Rhythm reported Q2 2026 earnings, with revenue of $71.26 million, beating estimates. The company is not yet profitable but has 89% gross margins and 54% revenue growth over the last year.
2 min readRhythm Pharmaceuticals (RYTM) announced Health Canada approved IMCIVREE for weight management in patients with acquired hypothalamic obesity, expanding its existing approvals. The drug is now indicated for patients aged four and older. The company expressed gratitude to the Canadian patient and healthcare community.
2 min readHealth Canada approved Rhythm Pharmaceuticals' Imcivree for weight management in patients aged 4+ with acquired hypothalamic obesity. The approval is based on a Phase 3 trial showing an 18.8% placebo-adjusted BMI reduction. Imcivree is also approved in the U.S., Europe, and the UK for other obesity-related indications.
2 min readRhythm Pharmaceuticals (RYTM) received Health Canada approval for IMCIVREE (setmelanotide) to treat weight management in patients 4 years and older with acquired hypothalamic obesity. The approval follows a Phase 3 trial showing an 18.8% placebo-adjusted BMI reduction. IMCIVREE is the first targeted therapy for this condition in Canada.
2 min readPalatin Technologies (PTN), valued at $20M, is developing melanocortin-receptor drugs for rare obesity, following Rhythm Pharmaceuticals (RYTM) and Neurocrine Biosciences' successes in the space. PTN's programs aim to improve efficacy and tolerability, with clinical trials expected to start in late 2026 and 2027. The market's validation of MC4R targets and rare-obesity drugs could significantly impact PTN's valuation.
2 min readMeeker David P (President and CEO) sold 50,000 shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) at an average of $102.67 ($101.75–$105.19, $5.13M total) across 5 trades on 2026-09-14 under a Rule 10b5-1 trading plan.
4 min readRhythm Pharmaceuticals (RYTM) insider David Meeker filed a Rule 144 notice to sell 50,000 shares, valued at $5.24M, acquired via option exercise on or after September 14, 2026, through Morgan Stanley.
1 min readRhythm Pharmaceuticals (RYTM) presented new data at the 64th ESPE Meeting, showing positive results for setmelanotide in treating paediatric acquired hypothalamic obesity, including BMI reductions and improved metabolic indices. Analysts note this strengthens the company's clinical story but does not alter its near-term financial losses. The data may support future regulatory and reimbursement progress, with analysts projecting significant revenue growth by 2029.
3 min readRhythm Pharmaceuticals (RYTM) presented data at ESPE 2026 showing setmelanotide reduced BMI and improved cardiometabolic markers in paediatric hypothalamic obesity patients. Real-world data from France showed mean BMI reductions of 11.5% at 6 months and 9.0% at 18 months. Phase 3 analyses showed significant improvements in metabolic indices compared to placebo.
3 min read
